$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
必妥维(Biktarvy)的详细说明书:作用与功效,用法用量,副作用,注意事项等
2025-10-19 11:44:20
Check Details
必妥维(Biktarvy)的副作用和不良反应
2025-10-19 11:44:20
Check Details
美国FDA批准必妥维(Biktarvy)新适应症,用于有治疗经历且正在重新开始抗逆转录病毒治疗的HIV感染者
2025-10-19 11:44:20
Check Details
必妥维(Biktarvy)中文说明书
2025-10-19 11:44:20
Check Details
必妥维(Biktarvy)的用法用量:用药指南,剂量调整,特殊人群用药
2025-10-19 11:44:20
Check Details
绥美凯(Triumeq)的详细说明书:作用与功效,用法用量,副作用,注意事项等
2025-10-19 11:44:20
Check Details
绥美凯(Triumeq)的副作用和不良反应
2025-10-19 11:44:20
Check Details
ViiVHealthcare宣布美国FDA批准绥美凯(Triumeq),这是首款含多替拉韦的分散型单一片剂方案,为感染HIV的儿童提供每日一次治疗u200bu200b
2025-10-19 11:44:20
Check Details
绥美凯(Triumeq)中文说明书
2025-10-19 11:44:20
Check Details
绥美凯(Triumeq)的用法用量:用药指南,剂量调整,特殊人群用药
2025-10-19 11:44:20
Check Details
福替沙韦(Fostemsavir)的详细说明书:作用与功效,用法用量,副作用,注意事项等
2025-10-19 11:44:20
Check Details
福替沙韦(Fostemsavir)的副作用和不良反应
2025-10-19 11:44:20
Check Details
1
2
...
4013
4014
4015
4016
4017
4018
4019
...
10230
10231
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Epclusa (Sofosbuvir/Velpatasvir) Pan-Genotypic HCV Treatment: Mechanism, Efficacy, and Dosing
2
Laos Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) Generic Guide: Efficacy, Regimen Selection, and Precautions
3
Finerenone: Indications, Dosing Strategy, and Combination Therapy
4
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor
5
Enasidenib: A Targeted IDH2 Inhibitor for Acute Myeloid Leukemia
6
Alpelisib: From Breast Cancer to PIK3CA-Related Overgrowth Spectrum
7
Ponatinib in Chronic Myeloid Leukemia: 5-Year Results from the OPTIC Trial
8
Erdafitinib Oral Tablets: Strengths, Packaging, and Dose Adjustment
9
Capmatinib (Tabrecta): Oral Targeted Therapy for MET Exon 14 Skipping-Mutated NSCLC
10
Amivantamab Plus Lazertinib: A Chemotherapy-Free First-Line Option in EGFR-Mutated NSCLC
11
Midostaurin (Rydapt): Dosing Essentials in FLT3-Mutated AML and Systemic Mastocytosis
12
Lapatinib: An Oral Dual EGFR/HER2 TKI in HER2-Positive Breast Cancer